The firm plans to integrate its technology with a compatible microfluidic sample prep method developed by researchers at Columbia University.
The Madison, Wisconsin-based company is expanding its global operations with distribution deals in Turkey, South Africa, Russia, and Australia.
The deal covers Circulogene's technology for enriching tumor DNA from small volumes of blood for next-generation sequencing-based analysis.
The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.
The firm plans to expedite cell sorting for research labs with an inexpensive device that uses piezoelectric actuators and disposable microfluidics.
The SBIR grant will support the development of the firm's single-cell analysis platform, Tapestri.
The company has been working for several years under NIH grants totaling more than $7 million and is now preparing for its first formal product launch.
The team developed an equipment-free dipstick device using untreated cellulose-based paper to quickly collect and purify genetic material for amplification.
LGC will offer NuGen's single-primer enrichment technology for next-generation sequencing target enrichment.
Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
The firm will advance an exosome isolation technology that it says allows for the capture of exosomes more efficiently and sensitively than existing platforms.
The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.
The researchers are working to develop portable sequencing solutions for outbreak surveillance and infectious disease diagnostics.
Startup TwinStrand Biosciences has licensed the method and is working on developing targeted assays, including for early detection of ovarian cancer.
The startup is launching an instrument that will process up to 10,000 single cells for DNA sequencing as well as a panel that will target AML genes.
The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.
The team tested 21 protocols for extracting DNA from human fecal microbiome samples to recommend one to improve comparability between studies.
Under an NIH grant, the firm plans to develop its Chicago method to analyze fecal metagenomic samples without relying on first culturing the bacteria.
Lexogen has commercialized the method, which involves labeling newly synthesized RNA, and said it would have applications in drug discovery pipelines.
Hangzhou Chengyuan Genomics will provide single-cell analysis services and sell 1CellBio's InDrop instrument, reagents, and kits in China.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.